Walaphage-G-1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride (1 mg) and Metformin (500 mg), indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and increasing peripheral insulin sensitivity. The combined action of these agents provides complementary mechanisms to effectively lower blood glucose levels in patients inadequately controlled by diet and exercise alone. Walaphage-G-1 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modification. It is important to monitor blood glucose regularly to adjust dosage and avoid hypoglycemia, a potential adverse effect due to enhanced insulin release. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily attributable to Metformin. Contraindications include severe renal impairment, metabolic acidosis, and hypersensitivity to either component. Caution is advised in patients with hepatic dysfunction or cardiovascular disease. This medication should be used under medical supervision with periodic assessment of renal function and glycemic status to optimize therapeutic outcomes and minimize risks.